The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

BOSTON (MarketWatch) -- Novartis AG said early Monday that its bone medication Reclast has also been approved by the Food and Drug Administration to treat postmenopausal osteoporosis. The drug, ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Two U.S. Food and Drug Administration advisory panels were jointly meeting on Friday over whether to recommend a "drug holiday" or otherwise clarify how long people should take a class of osteoporosis ...

Some say a new treatment for the bone-weakening disease is a breakthrough. May 2, 2007 — -- A new option in the treatment of osteoporosis could one day change the way many of the 10 million ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

For the first time, an osteoporosis drug has reduced deaths and prevented new fractures in elderly patients with broken hips, according to new research. Some experts called the drop in deaths ...

BOSTON (Reuters) - In a study that could change the way hip fractures are treated, doctors have discovered that giving the Novartis osteoporosis drug Reclast can prevent later fractures and helps ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.